

## Outline


- Mechanism of check point inhibitors
- Immune Related Adverse Events (irAEs)
  - Events we think about
  - Events that are common and we don't think about them
  - Rare Events
- Delayed Immune Related Events (DIRE)


11


## Mechanism























A 65 year old on pembrolizumab presents to the clinic for his second cycle of therapy. He has been feeling well. He has a mild macular rash here and there on the medial forearms. It is not pruritic. An example is shown in the photograph. Labs are normal. Can treatment be given today?














A 28 year old man is on ipilimumab (3mg/kg) and nivolumab (1mg/kg) every three weeks for metastatic melanoma to the lung. When he presented to the clinic before the start of his second cycle he reported that he had three loose stools per day for the last two days. There was no associated abdominal pain, blood in the stool or fever. On exam he appears well and VS are normal. Can you give him the treatment today? Increase of <4 stools per day Diarrhea ncrease of 4 - 6 stools per Increase of >=7 stools per day Life-threatening Death over baseline; mild increase in day over baseline; moderate over baseline; hospitalization consequences; urgent ostomy output compared to increase in ostomy output indicated; severe increase in intervention indicated baseline compared to baseline; ostomy output compared to limiting instrumental ADL baseline; limiting self care ADL Definition: A disorder chara nd/or loose or watery bowel movements.


The patient is admitted overnight for work up and IVF and he does well. He had only one loose stool in the hospital so he is discharged the next day. Two days later at his scheduled post hospital follow up he states that he had 7 watery bowel movements in the last 24 hours. On the two hour drive to clinic he felt feverish and had chills.


Temp 101.5. HR 140. The patient is flushed. Abdominal exam is slightly tender but no rebound.

WBC 12.5. Hg 11.5. Platelets 175. ANC 10. ALC 0.8. Lactate normal. Comprehensive metabolic parameters (CMP) are normal

### 27


# What is the diagnostic plan? Stool cultures C Difficile testing Stool calprotectin CT scan Gl consult Colonoscopy Quantiferon Gold Hepatitis Serology Pan Endocrine labs






## Diarrhea/Colitis


- Mild (Grade 1): <4 stools/day above baseline
  - Bland diet
  - Some recommend: loperamide +- diphenoxylate/atropine
  - May delay ipilimumab until symptoms improve
- Moderate (Grade 2):> or + to 4 to 6 stools/day
  - Consider colonoscopy,
  - 1-2mg/kg/d of methylprednisolone
  - Hold immunotherapy
  - If no response, continue treatment per grade >=3
- Severe (Grade >=3): >=7 stools/day
  - High dose steroids: 1-2 mg/kg of methylprednisolone or equivalent
  - Discontinue immunotherapy
  - If unresolved in 48 to 72 hours consider infliximab




A 48 year old woman with COPD and metastatic adenocarcinoma of the lung to the lung is admitted with "pneumonia". Her cancer was diagnosed 6 months ago, and treated with monthly nivolumab. Three months into the treatment, scans showed stable disease. On presentation she has a room air 02 Sat of 85%, BP of 135/80 and Temp 99. CT scan is shown.











A 65 year old is on ipilimumab and nivolumab for metastatic melanoma to the liver. He has had two treatments when he presents for an unscheduled visit with right upper quadrant abdominal pain and bloating. No fever No diarrhea but his stools have become lighter in color. CBC shows a mildly elevated WBC otherwise it is normal. AST 340, ALT 410, Alk phos 810, Total Bili 0.5, Protein 6.2, Albumin 3.8.






## Hepatitis

- Incidence
  - 30% on combined anti-CTLA and anti PD1
  - 10% on anti PD1 alone
- Time
  - 8 to 12 weeks in single agent regimens
  - Sooner in the combination
  - A waxing and waning picture may be seen with hepatitis induced by anti-CTLA-4
- Symptoms and signs
  - Usually based on elevated LFTs
  - Bloating, pain, dyspepsia, jaundice, nausea
  - Biopsy shows lymphocytic infiltrate







A 52 year old with advanced renal cell cancer on ipilimumab and nivolumab presents with neck pain and headache two weeks after his first cycle of treatment. He states that it was harder to drive to clinic because his peripheral vision is "off". Prior to starting the treatment he had a normal MRI of the brain.

On exam, 150/91, 37.2, 88, 96% resting comfortably. No focal neurologic findings.

Labs: 10am WBC 10.7, Hg 14.2, platelet 319, ALC 2.2, Na 129, K 5.2, chloride 99, CO2 26, creatinine 0.7, AST 26, ALT 62, Alk phos 61





A 54 year old man on ipi/nivo for melanoma metastatic to the brain presents for his third cycle. He has been "shaky" lately.


BP 134/74. HR 110. Temp 37.1 Exam is otherwise normal.


CBC and CMP are normal.

You send him up to infusion, waiting the TSH to come back.

60 minutes later you see the following labs.

- TSH < 0.015 (0.600-3.300 iIU/mL)
- Free T4 4.65 (0.71-1.40 ng/dl)







## Thyroid: High TSH, Low FT4 High TSH and nl FT4 in subclinical Hyperthyroid: Low TSH, high FT4, high FT3 Low TSH and nl fT4 in subclinical Graves disease: + Anti-thyroperoxidase antibodies and anti-thyroglobulin antibodies, Radioactive iodine uptake


### 47

# 5 Description of the state of the s



54 year old patient with NSSLC metastatic to liver on nivolumab presents for her third cycle of treatment. She is doing well but complains of pain in the left side of her mouth. On examination her oral mucosa is pink and dry. There are no abnormal lesions. She has no cervical lymphadenopathy. There is fullness over the left parotid gland.






## Arthralgia

- The typical adult with OA
- The young person with a injury from a skiing accident
- Gosh, my joints hurt more than they used to
- NSAIDS
- Integrate care with orthopedics Steroid injections







## Nephritis

- Nephritis: Not common but difficult to diagnosis. UA is a more appropriate screening test than Cr.
- Guidelines are creatinine driven
- Gold standard is a kidney biopsy

KEY CONCEPT 4: Do not forget the rare but serious side effects to the heart and nervous system

57


A 81 year old chemistry professor is treated with ipi/nivo for RCC metastatic to the lung. He is admitted to the ICU with chest pain and diagnosed with myocarditis. After stabilizing his heart and transferring the pt to the floor, his nurse calls the doctor for "abnormal breathing". It is observed that the pt is using his abdominal mm to breathe. His voice is weak and he states that he has difficulty swallowing. The pt went back to the ICU


Serum-negative myasthenia gravis was diagnosed Treated with 1000 mg methylprednisolone i.v. for 3


d, tapered to 80 mg per day


Pyridostigmine 30 mg BID G tube Plasmapheresis.


The pt was intubated for airway protection but he rapidly deteriorated and passed away on day 8.



















Beyond the usual toxicities...


But caution as oncolytic therapy could be included in patients with complex conditions.











# The management plan Dermatology Consult Burn Unit (considered) Steroids Mycophenolate (considered)











## **KEY CONCEPT 9**

- I/O management requires a team approach.
- UNC has a multidisciplinary team for this. It is led by Dr Rumey C. Ishizawar

# KEYs in one stroke Use the Common Toxicity Criteria for Adverse Events to Grade toxicity Management is based on the grade. Patients usually respond to steroids in a few days; if they don't, move to more aggressive management. Good PS pts who are treated with PD1i's have a low risk of grade 3 Toxicity risk depends on sequence, combination, new agents. Don't forget the rare but important risks to the CNS and heart. IrAES can be permanent, and recurrent (DIRE), even long after the treatment is done.

